Article Sidebar
Main Article Content
Research on Correlations of lncRNA ST7-AS1 with Progression and Therapeutic Targets of Esophageal Cancer
Main Article Content
Abstract
Background/Aims: Esophageal cancer is a highly prevalent gastrointestinal tumor in China, resulting in a significant number of deaths annually. In this paper, we investigated the regulatory role and therapeutic potential of aberrant ST7-AS1 expression in esophageal cancer.
Materials and Methods: The presence of ST7-AS1 in 125 esophageal cancer tissues was identified through RT-qPCR assays. The application of Kaplan-Meier to evaluate survival rates in patients with esophageal cancer. Cell activity was assessed by both CCK-8 and Transwell assays. The luciferase activity assay verified the association of ST7-AS1 with miR-4262.
Results: ST7-AS1 expression in esophageal cancer was noticeably overexpressed compared to the control group. Patients with upregulated ST7-AS1 had shorter survival rates. Silencing ST7-AS1 reduced the proliferation level of esophageal cancer cells, as did the migration and invasion levels. Mechanistically, ST7-AS1 acted as a sponge for miR-4262, affecting the progression of esophageal cancer. This was negatively correlated with ST7-AS1. Moreover, the miR-4262 inhibitor negated the inhibitory effect of silencing ST7-AS1 on cells.
Conclusion: Knockdown of ST7-AS1 may alleviate tumor progression by targeting miR-4262, indicating that ST7-AS1 is anticipated to serve as a therapeutic biomarker for patients with esophageal cancer.
Cite this article as: Lin X, Sun S, Zhang J, Cai Y, Cheng Q. Research on correlations of lncRNA ST7-AS1 with progression and therapeutic targets of esophageal cancer. Turk J Gastroenterol. 2025;36(2):82-88.
Article Details
References
1. Xu X, Xu Y, Wang J, et al. The controversy of esophageal carcinosarcoma: a case report and brief review of literature. Medicine. 2019;98(10):e14787. [CrossRef]
2. Wang B, Li M, Su A, et al. Prognostic value of GPNMB, EGFR, p-PI3K, and Ki-67 in patients with esophageal squamous cell carcinoma. Anal Cell Pathol (Amst). 2022;2022:9303081. [CrossRef]
3. Wang J, Zhao Q, Cai L, Li J, Chen S. Efficacy of bevacizumab and gemcitabine in combination with cisplatin in the treatment of esophageal cancer and the effect on the incidence of adverse reactions. BioMed Res Int. 2022;2022:2317181. [CrossRef]
4. Lai IL, Chang YS, Chan WL, et al. Male-specific long noncoding RNA TTTY15 inhibits non-small cell lung cancer proliferation and metastasis via TBX4. Int J Mol Sci. 2019;20(14). [CrossRef]
5. Yang C, Chen K. Long non-coding RNA in esophageal cancer: a review of research progress. Pathol Oncol Res. 2022;28:1610140. [CrossRef]
6. Xue ST, Cao SQ, Ding JC, et al. LncRNA LUESCC promotes esophageal squamous cell carcinoma by targeting the miR-6785-5p/NRSN2 axis. Cell Mol Life Sci. 2024;81(1):121. [CrossRef]
7. Li Y, Chen B, Jiang X, et al. A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma. Cell Rep. 2023;42(6):112542. [CrossRef]
8. Xue ST, Zheng B, Cao SQ, et al. Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis. Mol Cancer. 2022;21(1):69. [CrossRef]
9. Hu RH, Zhang ZT, Wei HX, et al. LncRNA ST7-AS1, by regulating miR-181b-5p/KPNA4 axis, promotes the malignancy of lung adenocarcinoma. Cancer Cell Int. 2020;20(1):568. [CrossRef]
10. Yang KD, Wang Y, Zhang F, et al. CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer. Mol Cell Biochem. 2022;477(11):2493-2505. [CrossRef]
11. Li Y, Qin JJ, Wang Z, et al. Surgical treatment for esophageal cancer during the outbreak of COVID-19. Zhonghua Zhong Liu Za Zhi. 2020;42(4):296-300. [CrossRef]
12. Ma YS, Liu JB, Wu TM, Fu D. New therapeutic options for advanced hepatocellular carcinoma. Cancer Control J Moffitt Cancer Cent. 2020;27(3):1073274820945975. [CrossRef]
13. Ma D, Wei J, Chen S, et al. Fucoidan inhibits the progression of hepatocellular carcinoma via causing lncRNA LINC00261 overexpression. Front Oncol. 2021;11:653902. [CrossRef]
14. Meng Z, Yang W, Zhu L, Liu W, Wang Y. A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma. Front Pharmacol. 2022;13:963072. [CrossRef]
15. Zhao S, Li P, Zhou G. Long noncoding RNAs in the prediction of survival of patients with digestive cancers. Turk J Gastroenterol. 2023;34(1):19-25. [CrossRef]
16. Huang T, You Q, Huang D, et al. A positive feedback between PDIA3P1 and OCT4 promotes the cancer stem cell properties of esophageal squamous cell carcinoma. Cell Commun Signal. 2024;22(1):60. [CrossRef]
17. Zhang Z, Zhang H, Li D, Zhou X, Wang J, Zhang Q. LncRNA ST7-AS1 is a potential novel biomarker and correlated with immune infiltrates for breast cancer. Front Mol Biosci. 2021;8:604261. [CrossRef]
18. Cai S, Weng Y, Liu P, Miao F. Knockdown of ST7-AS1 inhibits migration, invasion, cell cycle progression and induces apoptosis of gastric cancer. Oncol Lett. 2020;19(1):777-782. [CrossRef]
19. Qin H, Xu J, Gong L, Jiang B, Zhao W. The long noncoding RNA ST7-AS1 promotes laryngeal squamous cell carcinoma by stabilizing CARM1. Biochem Biophys Res Commun. 2019;512(1):34-40. [CrossRef]
20. Zong M, Feng W, Wan L, Yu X, Yu W. LncRNA TUG1 promotes esophageal cancer development through regulating PLK1 expression by sponging miR-1294. Biotechnol Lett. 2020;42(12):2537-2549. [CrossRef]
21. Huang GM, Zang HL, Geng YX, Li YH, FAM LR. LncRNA FAM83A-AS1 aggravates the malignant development of esophageal cancer by binding to miR-495-3p. Eur Rev Med Pharmacol Sci. 2020;24(18):9408-9415. [CrossRef]
22. Zhang C, Lian H, Xie L, Yin N, Cui Y. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. Biol Chem. 2020;401(9):1053-1061. [CrossRef]
23. Xu LJ, Yu XJ, Wei B, et al. LncRNA SNHG7 promotes the proliferation of esophageal cancer cells and inhibits its apoptosis. Eur Rev Med Pharmacol Sci. 2018;22(9):2653-2661. [CrossRef]
24. Lampropoulou DI, Pliakou E, Aravantinos G, Filippou D, Gazouli M. The role of exosomal non-coding RNAs in colorectal cancer drug resistance. Int J Mol Sci. 2022;23(3):1473. [CrossRef]
25. Wang K, Ren Y, Liu Y, Zhang J, He JJ. miR-4262 promotes proliferation and invasion of human breast cancer cells through directly targeting KLF6 and KLF15. Oncol Res. 2017;25(2):277-283. [CrossRef]
26. Ren L, Yang S, Cao Q, Tian J. CRNDE contributes cervical cancer progression by regulating miR-4262/ZEB1 axis. Onco Targets Ther. 2021;14:355-366. [CrossRef]
27. Weng L, Ma J, Jia YP, et al. MiR-4262 promotes cell apoptosis and inhibits proliferation of colon cancer cells: involvement of GALNT4. Am J Transl Res. 2018;10(12):3969-3977.
28. Song K, Liu N, Yang Y, Qiu X. Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262. Tumour Biol. 2016;37(5):6493-6499. [CrossRef]
29. Liu Z, Zhao C, Du S, Gao S, Lu L. MiR-4262 inhibits the development of esophageal cancer by negatively regulating KLF6 level. Exp Mol Pathol. 2020;115:104476. [CrossRef]